Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes

Show simple item record

dc.contributor.author Roehr, Charles Christoph C.
dc.contributor.author Banerjee, Rupjani
dc.contributor.author Alarcon-Allen, Ana
dc.contributor.author Dempsey, Eugene M.
dc.date.accessioned 2019-05-29T11:28:49Z
dc.date.available 2019-05-29T11:28:49Z
dc.date.issued 2019-02-25
dc.identifier.citation Roehr, C. C. C., Banerjee, R., Alarcon-Allen, A. and Dempsey, E. (2019) 'Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes', Cochrane Database of Systematic Reviews, Issue 2, CD013275 (9pp). doi: 10.1002/14651858.CD013275 en
dc.identifier.issued 2 en
dc.identifier.startpage 1 en
dc.identifier.endpage 9 en
dc.identifier.issn 1465-1858
dc.identifier.uri http://hdl.handle.net/10468/7998
dc.identifier.doi 10.1002/14651858.CD013275 en
dc.description.abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To review and summarise the existing evidence of the relationship between maternal methylxanthine (including caffeine) consumption (or by any other method of administration) versus no intervention, placebo or a different methylxanthine, before birth with the intention to influence outcomes in preterm newborns, with particular focus on cardiorespiratory adaptation at birth and long-term neurodevelopmental outcomes. en
dc.description.sponsorship National Institute for Health Research (Cochrane Infrastructure funding to Cochrane Pregnancy and Childbirth) en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher John Wiley & Sons, Ltd. on behalf of the Cochrane Collaboration en
dc.relation.uri https://doi.org//10.1002/14651858.CD013275
dc.rights © 2019, the Cochrane Collaboration. Published by John Wiley & Sons, Ltd. All rights reserved. en
dc.subject Methylxanthine en
dc.subject Caffeine en
dc.subject Cardiorespiratory adaptation en
dc.subject Neurodevelopmental outcomes en
dc.title Maternal antenatal methylxanthine (including caffeine) treatment for improving preterm outcomes en
dc.type Other en
dc.internal.authorcontactother Eugene Dempsey, Paediatrics & Child Health, University College Cork, Cork, Ireland. +353-21-490-3000 Email: g.dempsey@ucc.ie en
dc.internal.availability Full text available en
dc.check.info Access to this article is restricted until 12 months after publication by request of the publisher. en
dc.check.date 2020-02-25
dc.date.updated 2019-05-29T11:15:03Z
dc.description.version Published Version en
dc.internal.rssid 487025689
dc.contributor.funder National Institute for Health Research en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Cochrane Database of Systematic Reviews en
dc.internal.copyrightchecked Yes
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress g.dempsey@ucc.ie en
dc.identifier.articleid CD013275 en
dc.identifier.eissn 1469-493X


Files in this item

This item appears in the following Collection(s)

Show simple item record

This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement